Optimization of the HepaRG cell model for drug metabolism and toxicity studies

Toxicology in Vitro

Volumn 26, Issue 8, 2012, Pages 1278-1285

  Anthérieu, Sébastien ^a,b   Chesné, Christophe ^c   Li, Ruoya ^c   Guguen Guillouzo, Christiane ^a,b   Guillouzo, André ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c Biopredic international   (France)

Author keywords

CYP P450; Drug metabolism; HepaRG cells; Hepatocytes; Hepatotoxicity; Inducers

Indexed keywords

CYTOCHROME P450; DIMETHYL SULFOXIDE; XENOBIOTIC AGENT;

BIOLOGICAL MODEL; CELL DIFFERENTIATION; CELL LINE; CHEMISTRY; ENZYMOLOGY; HUMAN; LIVER CELL; METABOLISM; PATHOPHYSIOLOGY; REVIEW; TIME; TOXIC HEPATITIS;

CELL DIFFERENTIATION; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DIMETHYL SULFOXIDE; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; HUMANS; MODELS, BIOLOGICAL; TIME FACTORS; XENOBIOTICS;

MLCS; MLOWN;

EID: 85027942357     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.05.008     Document Type: Article

References (59)

1. Aninat, C., Piton, A., Glaise, D., Le Charpentier, T., Langouet, S., Morel, F., Guguen-Guillouzo, C., Guillouzo, A., Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34 (2006), 75–83.
2. Aninat, C., Seguin, P., Descheemaeker, P.N., Morel, F., Malledant, Y., Guillouzo, A., Catecholamines induce an inflammatory response in human hepatocytes. Crit Care Med 36 (2008), 848–854.
3. Antherieu, S., Chesne, C., Li, R., Camus, S., Lahoz, A., Picazo, L., Turpeinen, M., Tolonen, A., Uusitalo, J., Guguen-Guillouzo, C., Guillouzo, A., Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos 38 (2010), 516–525.
4. Antherieu, S., Rogue, A., Fromenty, B., Guillouzo, A., Robin, M.A., Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in heparg cells. Hepatology 53 (2011), 1895–1905.
5. Biour, M., Poupon, R., Grange, J.D., Chazouilleres, O., Drug-induced hepatotoxicity. The 13th updated edition of the bibliographic database of drug-related liver injuries and responsible drugs. Gastroenterol Clin Biol 24 (2000), 1052–1091.
6. Brien, J.F., Jimmo, S., Brennan, F.J., Ford, S.E., Armstrong, P.W., Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol 65 (1987), 360–364.
7. Cerec, V., Glaise, D., Garnier, D., Morosan, S., Turlin, B., Drenou, B., Gripon, P., Kremsdorf, D., Guguen-Guillouzo, C., Corlu, A., Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45 (2007), 957–967.
8. Darnell, M., Schreiter, T., Zeilinger, K., Urbaniak, T., Soderdahl, T., Rossberg, I., Dillner, B., Berg, A.L., Gerlach, J.C., Andersson, T.B., Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab Dispos 39 (2011), 1131–1138.
9. Donato, M.T., Martinez-Romero, A., Jimenez, N., Negro, A., Herrera, G., Castell, J.V., O'Connor, J.E., Gomez-Lechon, M.J., Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem Biol Interact 181 (2009), 417–423.
10. Dumont, J., Josse, R., Lambert, C., Antherieu, S., Laurent, V., Loyer, P., Robin, M.A., Guillouzo, A., Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines. Toxicol Appl Pharmacol 249 (2010), 91–100.
11. Dumont, J., Josse, R., Lambert, C., Antherieu, S., Le Hegarat, L., Aninat, C., Robin, M.A., Guguen-Guillouzo, C., Guillouzo, A., Differential toxicity of heterocyclic aromatic amines and their mixture in metabolically competent HepaRG cells. Toxicol Appl Pharmacol 245 (2010), 256–263.
12. Farrell, G.C., Larter, C.Z., Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006), S99–S112.
13. Freneaux, E., Labbe, G., Letteron, P., The Le, D., Degott, C., Geneve, J., Larrey, D., Pessayre, D., Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 8 (1988), 1056–1062.
14. Ged, C., Rouillon, J.M., Pichard, L., Combalbert, J., Bressot, N., Bories, P., Michel, H., Beaune, P., Maurel, P., The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28 (1989), 373–387.
15. Gilot, D., Loyer, P., Corlu, A., Glaise, D., Lagadic-Gossmann, D., Atfi, A., Morel, F., Ichijo, H., Guguen-Guillouzo, C., Liver protection from apoptosis requires both blockage of initiator caspase activities and inhibition of ASK1/JNK pathway via glutathione S-transferase regulation. J Biol Chem 277 (2002), 49220–49229.
16. Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C., Guguen-Guillouzo, C., Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99 (2002), 15655–15660.
17. Guguen-Guillouzo, C., Guillouzo, A., General review on in vitro hepatocyte models and their applications. Methods Mol. Biol 640 (2010), 1–40.
18. Guguen-Guillouzo, C., Corlu, A., Guillouzo, A., Stem cell-derived hepatocytes and their use in toxicology. Toxicology 270 (2010), 3–9.
19. Guillouzo, A., Liver cell models in in vitro toxicology. Environ Health Perspect 106:Suppl 2 (1998), 511–532.
20. Guillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F., Guguen-Guillouzo, C., The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 168 (2007), 66–73.
21. Halliwell, W.H., Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 25 (1997), 53–60.
22. Hart, S.N., Li, Y., Nakamoto, K., Subileau, E.A., Steen, D., Zhong, X.B., A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos 38 (2010), 988–994.
23. Hoekstra, R., Nibourg, G.A., van der Hoeven, T.V., Ackermans, M.T., Hakvoort, T.B., van Gulik, T.M., Lamers, W.H., Elferink, R.P., Chamuleau, R.A., The HepaRG cell line is suitable for bioartificial liver application. Int J Biochem Cell Biol 43 (2011), 1483–1489.
24. Jennen, D.G., Magkoufopoulou, C., Ketelslegers, H.B., van Herwijnen, M.H., Kleinjans, J.C., van Delft, J.H., Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci 115 (2010), 66–79.
25. Josse, R., Aninat, C., Glaise, D., Dumont, J., Fessard, V., Morel, F., Poul, J.M., Guguen-Guillouzo, C., Guillouzo, A., Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab Dispos 36 (2008), 1111–1118.
26. Josse, R., Dumont, J., Fautrel, A., Robin, M.A., Guillouzo, A., Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds. Toxicol Appl Pharmacol 258 (2012), 176–187.
27. Josse R, Rogue A, Lorge E and Guillouzo A (2012b) An adaptation of the human HepaRG cells to the in vitro micronucleus assay. Mutagenesis (in press).
28. Kanebratt, K.P., Andersson, T.B., Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36 (2008), 1444–1452.
29. Kanebratt, K.P., Andersson, T.B., HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36 (2008), 137–145.
30. Kaneko, A., Kato, M., Sekiguchi, N., Mitsui, T., Takeda, K., Aso, Y., In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells. Xenobiotica 39 (2009), 803–810.
31. Lahoz, A., Donato, M.T., Picazo, L., Castell, J.V., Gomez-Lechon, M.J., Assessment of cytochrome P450 induction in human hepatocytes using the cocktail strategy plus liquid chromatography tandem mass spectrometry. Drug Metab Lett 2 (2008), 205–209.
32. Lambert, C.B., Spire, C., Claude, N., Guillouzo, A., Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol 234 (2009), 345–360.
33. Le Bigot, J.F., Begue, J.M., Kiechel, J.R., Guillouzo, A., Species differences in metabolism of ketotifen in rat, rabbit and man: demonstration of similar pathways in vivo and in cultured hepatocytes. Life Sci 40 (1987), 883–890.
34. Lee, W.M., Drug-induced hepatotoxicity. N Engl J Med 349 (2003), 474–485.
35. Legendre, C., Hori, T., Loyer, P., Aninat, C., Ishida, S., Glaise, D., Lucas-Clerc, C., Boudjema, K., Guguen-Guillouzo, C., Corlu, A., Morel, F., Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur J Cancer 45 (2000), 2882–2892.
36. Le Hegarat, L., Dumont, J., Josse, R., Huet, S., Lanceleur, R., Mourot, A., Poul, J.M., Guguen-Guillouzo, C., Guillouzo, A., Fessard, V., Assessment of the genotoxic potential of indirect chemical mutagens in HepaRG cells by the comet and the cytokinesis-block micronucleus assays. Mutagenesis 25 (2010), 555–560.
37. Le Vee, M., Jigorel, E., Glaise, D., Gripon, P., Guguen-Guillouzo, C., Fardel, O., Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28 (2006), 109–117.
38. Lubberstedt, M., Muller-Vieira, U., Mayer, M., Biemel, K.M., Knospel, F., Knobeloch, D., Nussler, A.K., Gerlach, J.C., Zeilinger, K., HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods 63 (2011), 59–68.
39. Lullmann, H., Lullmann-Rauch, R., Wassermann, O., Drug-induced phospholipidosis II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit. Rev. Toxicol. 4 (1975), 185–218.
40. Madec, S., Cerec, V., Plee-Gautier, E., Antoun, J., Glaise, D., Salaun, J.P., Guguen-Guillouzo, C., Corlu, A., CYP4F3B expression is associated with differentiation of HepaRG human hepatocytes and unaffected by fatty acid overload. Drug Metab Dispos 39 (2011), 1987–1996.
41. McGill, M.R., Yan, H.M., Ramachandran, A., Murray, G.J., Rollins, D.E., Jaeschke, H., HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 53 (2011), 974–982.
42. McGinnity, D.F., Zhang, G., Kenny, J.R., Hamilton, G.A., Otmani, S., Stams, K.R., Haney, S., Brassil, P., Stresser, D.M., Riley, R.J., Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 37 (2009), 1259–1268.
43. Moya, M., Gomez-Lechon, M.J., Castell, J.V., Jover, R., Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact 184 (2010), 376–387.
44. Olson, H., Betton, G., Robinson, D., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32 (2000), 56–67.
45. Padda, M.S., Sanchez, M., Akhtar, A.J., Boyer, J.L., Drug-induced cholestasis. Hepatology 53 (2011), 1377–1387.
46. Park, B.K., Kitteringham, N.R., Maggs, J.L., Pirmohamed, M., Williams, D.P., The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45 (2005), 177–202.
47. Pernelle, K., Le Guevel, R., Glaise, D., Stasio, C.G., Le Charpentier, T., Bouaita, B., Corlu, A., Guguen-Guillouzo, C., Automated detection of hepatotoxic compounds in human hepatocytes using HepaRG cells and image-based analysis of mitochondrial dysfunction with JC-1 dye. Toxicol Appl Pharmacol 254 (2011), 256–266.
48. Petit, E., Langouet, S., Akhdar, H., Nicolas-Nicolaz, C., Guillouzo, A., Morel, F., Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol In Vitro 22 (2008), 632–642.
49. Poucell, S., Ireton, J., Valencia-Mayoral, P., Downar, E., Larratt, L., Patterson, J., Blendis, L., Phillips, M.J., Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 86 (1984), 926–936.
50. Reddy, J.K., Rao, M.S., Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290 (2006), G852–G858.
51. Rogue, A., Lambert, C., Josse, R., Antherieu, S., Spire, C., Claude, N., Guillouzo, A., Comparative gene expression profiles induced by PPARgamma and PPARalpha/gamma agonists in human hepatocytes. PLoS One, 6, 2011, e18816.
52. Rogue, A., Lambert, C., Spire, C., Claude, N., Guillouzo, A., Interindividual variability in gene expression profiles in human hepatocytes and comparison with HepaRG cells. Drug Metab Dispos 40 (2012), 151–158.
53. Rotmensch, H.H., Belhassen, B., Swanson, B.N., Shoshani, D., Spielman, S.R., Greenspon, A.J., Greenspan, A.M., Vlasses, P.H., Horowitz, L.N., Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med 101 (1984), 462–469.
54. Shaikh, N.A., Downar, E., Butany, J., Amiodarone–an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol Cell Biochem 76 (1987), 163–172.
55. Turpeinen, M., Tolonen, A., Chesne, C., Guillouzo, A., Uusitalo, J., Pelkonen, O., Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol In Vitro 23 (2009), 748–753.
56. Turpeinen, M., Uusitalo, J., Jalonen, J., Pelkonen, O., Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 24 (2005), 123–132.
57. Uetrecht, J., Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol. 21 (2008), 84–92.
58. Whalley, P.J., Adams, R.H., Combes, B., Tetracycline Toxicity in Pregnancy. Liver and Pancreatic Dysfunction. JAMA 189 (1964), 357–362.
59. Zanelli, U., Caradonna, N.P., Hallifax, D., Turlizzi, E., Houston, J.B., Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs. Drug Metab Dispos 40 (2012), 104–110.